FIELD: medicine.
SUBSTANCE: invention relates to endocrinology, genetics, nephrology, genetic engineering, biochemistry, and can be used for early prediction of the risk of developing diabetic nephropathy (DNP) in patients with type 1 diabetes mellitus. DNA is isolated from venous blood lymphocytes. The CYP2C19 (G681A) gene is genotyped by polymerase chain reaction followed by restriction analysis. If a patient has a heterozygous polymorphism G681A of the CYP2C19 gene and an excess of the activity of malondialdehyde (MDA), catalase (CAT), glutathione-S-transferase (G-ST) and superoxide dismutase (SOD) over the reference values — indicators of the control group of healthy donors, the high risk of developing NPD is predicted.
EFFECT: method allows at an early stage to reliably and informatively predict the risk of developing rapidly progressive nephropathy, to take timely measures to correct this condition and to prevent the early development of such severe complications of DNP as anemia, arterial hypertension, pathology of phosphorus-calcium metabolism, dyslipidemia, proteinuria, etc. due to determination of heterozygous polymorphism G681A of the CYP2C19 gene and excess activity of MDA, CAT, G-ST and SOD in a patient.
1 cl, 1 tbl, 1 ex
